Literature DB >> 16225593

The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.

R B Warren1, C E M Griffiths.   

Abstract

The study of pharmacogenetics will optimize the use of systemic therapies in dermatology. Directed prescription of azathioprine dependent on phenotypic expression of the thiopurine methyltransferase gene is now accepted practice. To some extent other, older drugs have been neglected. We look at the role that pharmacogenetics could play in the use of methotrexate for psoriasis, focusing on known polymorphisms in the folate metabolic pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225593     DOI: 10.1111/j.1365-2133.2005.06880.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.

Authors:  Marina Talamonti; Marco Galluzzo; Arianna Zangrilli; Marina Papoutsaki; Colin Gerard Egan; Mauro Bavetta; Sara Tambone; Maria Concetta Fargnoli; Luca Bianchi
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

Review 2.  Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.

Authors:  Laura J Savage; Miriam Wittmann; Dennis McGonagle; Philip S Helliwell
Journal:  Rheumatol Ther       Date:  2015-03-17

3.  Dermatology: future therapeutic perspectives.

Authors:  Richard B Warren; Alan Menter
Journal:  Dermatol Ther (Heidelb)       Date:  2013-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.